Pomalyst - Celgene

Cost: $147,302 per U.S. patient per year

When Celgene's oral multiple myeloma drug was approved early in 2013, the company indicated it would be priced only a little higher than competitor Kyprolis (carfilzomib) from Onyx Pharmaceuticals ($ONXX), which had hit the market 7 months earlier. But EvaluatePharma says that its figures show a year's course of Pomalyst ran $147,302 last year, compared to $117,750 for Kyprolis.

Celgene ($CELG) certainly has experience in the premium pricing area. It owns Revlimid, with which Pomalyst also competes, and which comes in tenth on this list at a yearly cost of $128,666 in 2013.

No doubt, when the company priced Pomalyst, it was thinking about how it would fit into CEO Bob Hugin's plan to double sales at Celgene to $12 billion by 2017. Pomalyst had sales of $305.4 million in 2013 and has racked up sales of $296.5 million in the first half of this year, a 213% increase over H1 last year when it was still being rolled out.

And there is lots of upside potential. It is estimated that the multiple myeloma market will grow by about 60% to more than $7 billion by 2021.

For more:
Celgene looks to double its sales by 2017 on wave of cancer drug growth
New Celgene drug packs punch for multiple myeloma market

-- Eric Palmer (email | Twitter)

Pomalyst - Celgene

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

A phase 1 study of the Inlyta-Keytruda regimen, which bears a first-line nod for kidney cancer, got the ax along with several Bavencio tests.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.